Logo

Asterand to Use Rubicon s Whole-Genome Amplification Technology for Diabetes Research

May 26, 2004

NEW YORK, May 26 (GenomeWeb News) - Tissue-banking firm Asterand will use DNA amplification technology developed by Rubicon Genomics as part of a collaborative diabetes study, Asterand said today.

 

Asterand said it will use Rubicon's GenomePlex whole-genome amplification technology to obtain DNA samples from relatives of diabetes patients in a collaborative study that involves researchers from WayneStateUniversity and elsewhere.

 

The trial will collect blood samples from people suffering from diabetes, but other family members "may prefer a simple mouthwash, and by using this new amplification technology we can get the information we need," said Asterand CSO James Eliason.

 

Asterand said it will begin using the amplification method in Europe this month.

Breaking News
The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.